Cardiogenesis Corporation, a CryoLife, Inc. company, designs, develops, and distributes innovative devices for the treatment of advanced coronary artery disease. The company’s market leading transmyocardial revascularization (TMR) technology platform utilizes a holmium:YAG laser energy source delivered through a range of minimally invasive fiberoptic delivery systems.
Published long term results demonstrate the efficacy of the TMR treatment in patients suffering from severe refractory angina, when stenting or bypass surgery is no longer an option. The company is building on the TMR platform in combining laser treatment with the delivery of autologous cell therapy in a single delivery system. This PHOENIX combination delivery system has a CE Mark.